Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655911 · ClinicalTrials.gov registry record
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
A clinical trial, sponsored by Abeona Therapeutics.
- Terminated
- Registry status
- 1
- Enrollment target
NCT04655911 is a clinical trial that was terminated before completion, run by Abeona Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT04655911 was terminated before completion, sponsored by Abeona Therapeutics.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 years post-treatment).
Interventions
- BIOLOGICAL ABO-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2022-04-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655911
The ClinicalTrials.gov registry entry for NCT04655911 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abeona Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABO-101 is the first listed.
NCT04655911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04655911 about?
NCT04655911 is a clinical study titled "A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101". This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 year...
What is the current status of trial NCT04655911?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2020-10-28. Estimated completion is 2022-04-07.
What interventions are being tested in trial NCT04655911?
The interventions under investigation include: ABO-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04655911?
This trial is sponsored by Abeona Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.